ECM
QNCX icon

Evolution Capital Management’s Quince Therapeutics QNCX Stock Holding History

Evolution Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-885
Closed -$393K – 61
2022
Q2 		$393K Buy
+885
New +$626K 0.59% 19

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Evolution Capital Management's QNCX Position: Q3 2022 in Review

Evolution Capital Management sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 885 shares — an estimated $393K sold.

Evolution Capital Management first reported a position in QNCX in Q2 2022 and held it in 1 quarter. The position peaked at $393K in Q2 2022. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

  • Evolution Capital Management reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Evolution Capital Management sold 885 Quince Therapeutics shares in Q3 2022, an estimated $393K.
  • Evolution Capital Management first reported a position in Quince Therapeutics in Q2 2022 and held it in 1 quarter.
  • Evolution Capital Management's Quince Therapeutics position peaked at $393K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on Evolution Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.